Validated WES Assay for Biomarker Discovery and Clinical Development

This slide presentation highlights approaches to biomarker discovery and clinical development using a validated WES assay, demonstrating how advanced analytical technologies can support more robust biomarker strategies in modern drug development.

The slides also explore the application of CLSI H62 guidance to the validation of high-parameter spectral flow cytometric assays, supporting analytical rigor and reproducibility in complex flow cytometry–based biomarker studies.